Purpose Belimumab (BEL), a recombinant human monoclonal antibody directed against B-cell activating factor (BAFF), is the first approved biological agent for patients with systemic lupus erythematosus ...

Background Adverse childhood experiences (ACEs) have been linked to poorer adult health outcomes. ACEs may be a risk factor for heightened disease activity among Black American women living with ...

Background Low-dose IL-2 supplementation is a promising treatment of SLE. However, in most of current studies, lack of appropriate control groups lead to uncertainty on its efficacy. We conducted a ...

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

In the absence of cures for multi-system inflammatory disease, therapies aim to dampen long-term inflammation, control symptoms and prevent tissue damage. Glucocorticoids (GC) are a key ...

The landscape of therapeutic options for severe lupus nephritis (LN) is expanding. While the standard therapy is dual immunosuppression with glucocorticoid and either mycophenolate or cyclophosphamide ...

Background Modified immune cells (MICs) are mononuclear cells that gain immunosuppressive properties after incubation with the proliferation inhibitor mitomycin C. We showed that syngeneic MIC cell ...

Background Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are challenging ...

Objective This systematic review seeks to survey existing literature concerning systemic lupus erythematosus (SLE)-related thrombosis risk mechanisms within six pro-coagulable categories: ...

Background Single-cell RNA-sequencing (scRNA-seq) has been recently applied in systemic lupus erythematosus (SLE) to define distinct cellular composition and transcriptional signatures, greatly ...

O37 Male gender, educational level, disease activity, prednisone daily dose and previous medical adherence are predictive of medical adherence in systemic lupus erythematosus patients – Data from the ...

Background Abnormalities of type I interferon signaling and production can initiate lupus development. Disturbances of nucleic acid-sensing molecules triggered autoreactivity in lupus mouse models.